Adaptive Biotechnologies annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies EBITDA Growth & History (ADPT)
Adaptive Biotechnologies's calculated EBITDA was −$41.1M for fiscal 2025.
View full Adaptive Biotechnologies company overviewAdaptive Biotechnologies annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$41.1M | $104.0M | — |
| 2024 | 2024-12-31 | −$145.1M | $62.3M | — |
| 2023 | 2023-12-31 | −$207.4M | −$28.2M | — |
| 2022 | 2022-12-31 | −$179.3M | $15.7M | — |
| 2021 | 2021-12-31 | −$195.0M | −$50.7M | — |
| 2020 | 2020-12-31 | −$144.3M | −$73.7M | — |
| 2019 | 2019-12-31 | −$70.6M | −$26.8M | — |
| 2018 | 2018-12-31 | −$43.8M | −$5.1M | — |
| 2017 | 2017-12-31 | −$38.7M | — | — |
Adaptive Biotechnologies quarterly ebitda
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$12.1M | $8.9M | — |
| Q1 2026 | 2026-03-31 | −$15.8M | $9.5M | — |
| Q4 2025 | 2025-12-31 | −$9.1M | $21.2M | — |
| Q3 2025 | 2025-09-30 | $14.3M | $42.7M | — |
| Q2 2025 | 2025-06-30 | −$21.0M | $21.8M | — |
| Q1 2025 | 2025-03-31 | −$25.3M | $18.2M | — |
| Q4 2024 | 2024-12-31 | −$30.3M | $38.0M | — |
| Q3 2024 | 2024-09-30 | −$28.5M | $16.7M | — |
| Q2 2024 | 2024-06-30 | −$42.7M | −$582,000 | — |
| Q1 2024 | 2024-03-31 | −$43.5M | $8.2M | — |
| Q4 2023 | 2023-12-31 | −$68.3M | −$34.4M | — |
| Q3 2023 | 2023-09-30 | −$45.2M | −$5.1M | — |
| Q2 2023 | 2023-06-30 | −$42.2M | $5.1M | — |
| Q1 2023 | 2023-03-31 | −$51.8M | $6.2M | — |
| Q4 2022 | 2022-12-31 | −$33.9M | $22.8M | — |
| Q3 2022 | 2022-09-30 | −$40.0M | $12.7M | — |
| Q2 2022 | 2022-06-30 | −$47.3M | −$447,000 | — |
| Q1 2022 | 2022-03-31 | −$58.0M | −$19.4M | — |
| Q4 2021 | 2021-12-31 | −$56.7M | −$14.9M | — |
| Q3 2021 | 2021-09-30 | −$52.8M | −$17.9M | — |
| Q2 2021 | 2021-06-30 | −$46.9M | −$11.9M | — |
| Q1 2021 | 2021-03-31 | −$38.6M | −$6.0M | — |
| Q4 2020 | 2020-12-31 | −$41.9M | −$19.8M | — |
| Q3 2020 | 2020-09-30 | −$34.9M | −$18.9M | — |
| Q2 2020 | 2020-06-30 | −$34.9M | −$20.7M | — |
| Q1 2020 | 2020-03-31 | −$32.6M | −$14.4M | — |
| Q4 2019 | 2019-12-31 | −$22.1M | — | — |
| Q3 2019 | 2019-09-30 | −$16.0M | −$8.3M | — |
| Q2 2019 | 2019-06-30 | −$14.2M | — | — |
| Q1 2019 | 2019-03-31 | −$18.3M | — | — |
| Q3 2018 | 2018-09-30 | −$7.7M | — | — |
Adaptive Biotechnologies ebitda trends
Over the last five fiscal years, Adaptive Biotechnologies's ebitda increased from −$144.3M to −$41.1M, a change of $103.2M. The latest reported quarter, Q2 2026, shows −$12.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptive Biotechnologies source filings ↗Community posts
Adaptive reports broader NCCN guidance for residual-disease testing
Adaptive ($ADPT) Biotechnologies said updated National Comprehensive Cancer Network guidance for multiple myeloma gives measurable residual disease testing a dedicated section and names clonoSEQ as a testing option. The update specifies a p ...
